Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Primary Myelofibrosis 12Polycythemia Vera 11Myelodysplastic Syndromes 10Leukemia 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Myeloproliferative Disorders 8Recurrence 6Leukemia, Myelomonocytic, Chronic 6Hematologic Neoplasms 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, T-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Graft vs Host Disease 5Thrombocythemia, Essential 4Leukemia, Myeloid, Chronic-Phase 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2

Interventions

Blood Specimen Collection 3ibrutinib 2Rituximab 2Imatinib Mesylate 2ziconotide 1ruxolitinib 1ponatinib 1ofatumumab 1nilotinib 1lonafarnib 1fludarabine 1bosutinib 1Surveys and Questionnaires 1Specimen Handling 1SLC25A33 protein, human 1Povidone-Iodine 1Physical Therapy Modalities 1Pentostatin 1Lenalidomide 1Dasatinib 1Cyclophosphamide 1Bone Marrow Transplantation 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bronchiolitis Obliterans Syndrome × ruxolitinib × Clear all
NCT05413356 2022-10-19

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
50 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡